Liquidia Corporation (LQDA) stock news
The latest Liquidia Corporation news and press releases. 0 news stories in the last 24 hours, 0 times its usual daily coverage. LQDA stock report · Market news
Latest news
- Liquidia: Yutrepia's PAH Franchise Has Room To Grow Seeking Alpha, Nov 14, 2:15 PM UTC
Liquidia kept the right to market YUTREPIA for PAH after the settlement with United Therapeutics. This settlement limits YUTREPIA's potential in PH-ILD, but since it can still be sold to patients using it and to patie... - LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales Zacks Investment Research, Nov 11, 6:40 PM UTC
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth. - LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook Zacks Investment Research, Nov 11, 4:01 PM UTC
Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions. - Liquidia (NASDAQ:LQDA) Stock Price Breaks Above Fifty Day Moving Average Following Weak Earnings Defense World, Nov 11, 9:02 AM UTC
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares crossed above its 50 day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a 50 day moving aver... - Liquidia Q3 Earnings Call Highlights MarketBeat, Nov 10, 6:16 PM UTC
Liquidia NASDAQ: LQDA reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a p... - Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript Seeking Alpha, Nov 10, 6:01 PM UTC
Liquidia Corporation (LQDA) Q3 2026 Earnings Call Transcript - Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates Zacks Investment Research, Nov 10, 1:41 PM UTC
Liquidia Corporation (LQDA) came out with quarterly earnings of $0.8 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to a loss of $0.04 per share a year ago. - Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect? Zacks Investment Research, Oct 28, 4:50 PM UTC
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress. - LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Zacks Investment Research, Oct 14, 6:41 PM UTC
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label. - Liquidia shares surge 25% as settlement ends United Therapeutics litigation Proactive Investors, Oct 14, 5:16 PM UTC
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust ... - United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42% 24/7 Wall Street, Oct 14, 3:05 PM UTC
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank. - Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday Benzinga, Oct 14, 2:02 PM UTC
U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday. - This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario. Barrons, Oct 14, 12:57 PM UTC
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug. - Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky GuruFocus, Oct 12, 7:00 PM UTC
Liquidia Corporation (LQDA) Securities Investigation Notice - Levi and KorsinskyPR NewswireNEW YORK, Oct. 12, 2026Liquidia shareholders took a roughly 57% loss af - Liquidia (NASDAQ:LQDA) Shares Gap Up – Here’s Why Defense World, Oct 12, 3:02 PM UTC
Liquidia Corporation (NASDAQ: LQDA - Get Free Report)'s stock price gapped up prior to trading on Monday. The stock had previously closed at $27.38, but opened at $29.27. Liquidia shares last traded at $29.0220, with ... - LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law GuruFocus, Oct 8, 3:00 AM UTC
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv - Liquidia (NASDAQ:LQDA) Stock Price Down 6.1% After Analyst Downgrade Defense World, Oct 5, 2:20 PM UTC
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares dropped 6.1% on Monday after Wells Fargo and Company downgraded the stock from an overweight rating to an equal weight rating. Wells Fargo and Company now h... - Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback Zacks Investment Research, Oct 1, 6:31 PM UTC
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook. - UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% Zacks Investment Research, Oct 1, 5:20 PM UTC
United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products. - United Therapeutics Won Its Patent War and Liquidia Collapsed 24/7 Wall Street, Oct 1, 3:07 PM UTC
A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled. - United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia Benzinga, Oct 1, 12:14 PM UTC
Shares of United Therapeutics Corp. (NASDAQ:UTHR) are rising in Thursday morning trading following a federal court victory in its patent litigation against competitor Liquidia Corp. - Liquidia slumps after US court rules for United Therapeutics in patent fight Reuters, Sep 30, 7:41 PM UTC
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commercial outlook. - Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail Risk Seeking Alpha, Sep 30, 7:00 PM UTC
YUTREPIA's adoption is translating into profits and cash, giving Liquidia an operating foundation for further growth. LQDA is already generating substantial cash flows, even though YUTREPIA's growth phase remains in i... - LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? Zacks Investment Research, Sep 30, 6:50 PM UTC
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline. - Liquidia (NASDAQ:LQDA) Shares Up 4.2% – Time to Buy? Defense World, Sep 30, 10:21 AM UTC
Liquidia Corporation (NASDAQ: LQDA - Get Free Report) shares traded up 4.2% on Monday. The stock traded as high as $69.94 and last traded at $71.30. 96,947 shares changed hands during mid-day trading, a decline of 94%... - Is It Too Late to Buy Liquidia Corp (LQDA) After 7.7% Rally? GF Value Says Undervalued GuruFocus, Sep 28, 10:49 PM UTC
On September 28, 2026, Liquidia Corp (LQDA) shares rose by 7.7%, reaching a current price of $73.67. This impressive move comes within a 52-week range of $21.35 - Can LQDA's Yutrepia Outpace Intensifying PAH Competition? Zacks Investment Research, Sep 23, 4:16 PM UTC
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum. - LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? Zacks Investment Research, Sep 11, 7:26 PM UTC
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook. - Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio? Zacks Investment Research, Sep 10, 6:40 PM UTC
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug. - Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition? Zacks Investment Research, Aug 31, 3:16 PM UTC
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Press releases
- Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference GlobeNewsWire, Nov 10, 1:00 PM UTC
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial O... - Liquidia Corporation Reports Third Quarter 2026 Financial Results GlobeNewsWire, Nov 10, 11:30 AM UTC
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory an... - Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026 GlobeNewsWire, Nov 3, 1:30 PM UTC
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory an... - Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH GlobeNewsWire, Oct 13, 9:44 PM UTC
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory an... - Liquidia Corporation (LQDA) Securities Investigation Notice - Levi & Korsinsky PRNewsWire, Oct 12, 6:55 PM UTC
Liquidia shareholders took a roughly 57% loss after a court found that Yutrepia infringed two valid United Therapeutics patent claims. The investigation concerns whether investors had an accurate picture of that litig... - Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Liquidia Corporation (LQDA) GlobeNewsWire, Oct 8, 2:18 PM UTC
A reported 57% plunge followed a court finding against Yutrepia. That market reaction is now the focus of a Levi & Korsinsky investigation into potential securities law violations A reported 57% plunge followed a cour... - LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law Business Wire, Oct 8, 2:50 AM UTC
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law. - LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation PRNewsWire, Oct 6, 6:39 PM UTC
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pending investigati... - Liquidia Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Liquidia (LQDA) PRNewsWire, Oct 5, 9:45 PM UTC
LQDA shareholders who lost money after a court found that Yutrepia infringed two valid United Therapeutics patent claims may have the right to seek recovery. The investigation includes Liquidia's forecast of more than... - United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia Business Wire, Sep 30, 11:09 PM UTC
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District ... - Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent GlobeNewsWire, Sep 30, 5:20 PM UTC
District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's consideration wit... - FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis GlobeNewsWire, Sep 3, 11:30 AM UTC
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy ...
Headlines link to their publishers. Research data, not investment advice.